お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1000970

尿路感染症の世界市場:薬剤クラス別(アミノグリコシド、アゾール、キノロン、B-ラクタム)、臨床適応症別(膀胱炎、腎盂腎炎、尿道炎)、エンドユーザー別の市場調査、予測(~2025年)、COVID-19の累積的な影響

Urinary Tract Infection Market Research Report by Drug Class (Aminoglycosides, Azoles, Quinolones, and B-lactam), by Clinical Indication (Cystitis, Pyelonephritis, and Urethritis), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
尿路感染症の世界市場:薬剤クラス別(アミノグリコシド、アゾール、キノロン、B-ラクタム)、臨床適応症別(膀胱炎、腎盂腎炎、尿道炎)、エンドユーザー別の市場調査、予測(~2025年)、COVID-19の累積的な影響
出版日: 2021年04月12日
発行: 360iResearch LLP
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の尿路感染症の市場規模は、2020年の71億2,798万米ドルから、2025年末までに94億8,814万米ドルに成長すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮した、COVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

 

当レポートでは尿路感染症の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、薬剤クラス・臨床適応症・エンドユーザー・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査のために考慮された年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画の作成
    • 実行:調査の実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • 市場の見通し
  • 薬剤クラスの見通し
  • 臨床適応症の見通し
  • エンドユーザーの見通し
  • 地域の見通し
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズのファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 薬剤クラス別

  • アミノグリコシド
  • アゾール
  • キノロン
  • B-ラクタム

第7章 臨床適応症別

  • 膀胱炎
  • 腎盂腎炎
  • 尿道炎

第8章 エンドユーザー別

  • 病院
  • 自己管理

第9章 南北アメリカ

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第11章 欧州、中東・アフリカ

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第13章 企業のユーザビリティプロファイル

  • Allergan plc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Inc.
  • Eli Lilly and Company,
  • F. Hoffmann La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck & Co., Inc.
  • Mindray Medical International Limited
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Siemens Healthcare
  • Sun Pharmaceuticals Ltd.
  • Teva Pharmaceuticals
  • Urit Medical Electronic Group Co., Ltd.

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET: MARKET DYNAMICS
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2025
  • FIGURE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, 2020 VS 2025 (USD MILLION)
  • FIGURE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, 2020 VS 2025 (USD MILLION)
  • FIGURE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, 2020 VS 2025 (USD MILLION)
  • FIGURE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 VS 2025 (%)
  • FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2025
  • FIGURE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 VS 2025 (%)
  • FIGURE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025
  • FIGURE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, 2020 VS 2025 (USD MILLION)
  • FIGURE 29. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 30. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 32. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 33. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 34. CANADA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 35. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 36. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 37. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 38. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 40. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 41. CHINA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 42. INDIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 43. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 47. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 48. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 49. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 50. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 52. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. ITALY URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. QATAR URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 61. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 62. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 63. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX
  • FIGURE 64. GLOBAL URINARY TRACT INFECTION MARKET: MARKET SHARE ANALYSIS
  • FIGURE 65. GLOBAL URINARY TRACT INFECTION MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 66. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL URINARY TRACT INFECTION MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. CANADA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. CHINA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. INDIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. ITALY URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. QATAR URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. GLOBAL URINARY TRACT INFECTION MARKET: SCORES
  • TABLE 103. GLOBAL URINARY TRACT INFECTION MARKET: BUSINESS STRATEGY
  • TABLE 104. GLOBAL URINARY TRACT INFECTION MARKET: PRODUCT SATISFACTION
  • TABLE 105. GLOBAL URINARY TRACT INFECTION MARKET: RANKING
  • TABLE 106. GLOBAL URINARY TRACT INFECTION MARKET: MERGER & ACQUISITION
  • TABLE 107. GLOBAL URINARY TRACT INFECTION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 108. GLOBAL URINARY TRACT INFECTION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 109. GLOBAL URINARY TRACT INFECTION MARKET: INVESTMENT & FUNDING
  • TABLE 110. GLOBAL URINARY TRACT INFECTION MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 111. GLOBAL URINARY TRACT INFECTION MARKET: LICENSE & PRICING
目次
Product Code: MRR-0030336

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Urinary Tract Infection Market is expected to grow from USD 7,127.98 Million in 2020 to USD 9,488.14 Million by the end of 2025.

2. The Global Urinary Tract Infection Market is expected to grow from EUR 6,249.95 Million in 2020 to EUR 8,319.38 Million by the end of 2025.

3. The Global Urinary Tract Infection Market is expected to grow from GBP 5,556.21 Million in 2020 to GBP 7,395.94 Million by the end of 2025.

4. The Global Urinary Tract Infection Market is expected to grow from JPY 760,736.35 Million in 2020 to JPY 1,012,625.05 Million by the end of 2025.

5. The Global Urinary Tract Infection Market is expected to grow from AUD 10,350.77 Million in 2020 to AUD 13,778.04 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Urinary Tract Infection to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Class, the Urinary Tract Infection Market studied across Aminoglycosides, Azoles, Quinolones, and B-lactam.

Based on Clinical Indication, the Urinary Tract Infection Market studied across Cystitis, Pyelonephritis, and Urethritis.

Based on End User, the Urinary Tract Infection Market studied across Hospitals and Self-Administered.

Based on Geography, the Urinary Tract Infection Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Urinary Tract Infection Market including Allergan plc, AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Cipla Inc., Eli Lilly and Company,, F. Hoffmann La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Merck & Co., Inc., Mindray Medical International Limited, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Siemens Healthcare, Sun Pharmaceuticals Ltd., Teva Pharmaceuticals, and Urit Medical Electronic Group Co., Ltd..

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Urinary Tract Infection Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Urinary Tract Infection Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Urinary Tract Infection Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Urinary Tract Infection Market?

4. What is the competitive strategic window for opportunities in the Global Urinary Tract Infection Market?

5. What are the technology trends and regulatory frameworks in the Global Urinary Tract Infection Market?

6. What are the modes and strategic moves considered suitable for entering the Global Urinary Tract Infection Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Clinical Indication Outlook
  • 3.5. End User Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and kidney stones
      • 5.1.1.2. Rise in the awareness among people regarding urinary tract infections owing to rising healthcare expenditure
      • 5.1.1.3. Emergence of portable and battery-operated urinary tract infections devices
    • 5.1.2. Restraints
      • 5.1.2.1. Complicated regulated monitoring
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in adoption of urinary tract infections in emerging economies
      • 5.1.3.2. Rise in R&D of a novel class of antibiotics for urinary tract infections
    • 5.1.4. Challenges
      • 5.1.4.1. Complex clinical trials for designing antibacterial drugs that require an informative, ethical, and scientific approach
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Urinary Tract Infection Market, By Drug Class

  • 6.1. Introduction
  • 6.2. Aminoglycosides
  • 6.3. Azoles
  • 6.4. Quinolones
  • 6.5. B-lactam

7. Global Urinary Tract Infection Market, By Clinical Indication

  • 7.1. Introduction
  • 7.2. Cystitis
  • 7.3. Pyelonephritis
  • 7.4. Urethritis

8. Global Urinary Tract Infection Market, By End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. South Korea
  • 10.10. Thailand

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis
  • 12.4. Competitor SWOT Analysis
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Allergan plc
  • 13.2. AstraZeneca plc
  • 13.3. Bayer AG
  • 13.4. Boehringer Ingelheim GmbH
  • 13.5. Cipla Inc.
  • 13.6. Eli Lilly and Company,
  • 13.7. F. Hoffmann La Roche Ltd
  • 13.8. GlaxoSmithKline plc
  • 13.9. Johnson & Johnson
  • 13.10. Merck & Co. Inc.
  • 13.11. Merck & Co., Inc.
  • 13.12. Mindray Medical International Limited
  • 13.13. Mylan N.V.
  • 13.14. Novartis AG
  • 13.15. Novo Nordisk A/S
  • 13.16. Pfizer Inc.
  • 13.17. Siemens Healthcare
  • 13.18. Sun Pharmaceuticals Ltd.
  • 13.19. Teva Pharmaceuticals
  • 13.20. Urit Medical Electronic Group Co., Ltd.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.